P S McKinnon
Overview
Explore the profile of P S McKinnon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
231
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McKinnon P, Yu V
Eur J Clin Microbiol Infect Dis
. 2004 Mar;
23(4):231-2.
PMID: 15024627
No abstract available.
2.
McKinnon P, Davis S
Eur J Clin Microbiol Infect Dis
. 2004 Mar;
23(4):271-88.
PMID: 15015030
This review outlines some of the many factors a clinician must consider when selecting an antimicrobial dosing regimen for the treatment of infection. Integration of the principles of antimicrobial pharmacology...
3.
McKinnon P, Goff D, Kern J, Devlin J, Barletta J, Sierawski S, et al.
Arch Surg
. 2001 Dec;
136(12):1401-8; discussion 1409.
PMID: 11735868
Hypothesis: Risk factors for Candida infection in surgical intensive care units (SICUs) change over time. Risk factor progression may influence Candida colonization and infection. Design: Multicenter cohort survey. Setting: Three...
4.
Jellison T, McKinnon P, Rybak M
Pharmacotherapy
. 2001 Feb;
21(2):142-8.
PMID: 11213849
Study Objective: To evaluate epidemiology, resistance, and treatment outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam for 72 hours or longer. Design: Retrospective analysis. Setting: University teaching hospital....
5.
McKinnon P, Tam V
Support Care Cancer
. 2001 Jan;
9(1):8-10.
PMID: 11147147
A continued increase in the expression of resistance among bacterial pathogens has prompted the development of a variety of new compounds directed against resistant strains of bacteria. Recently, the most...
6.
Tam V, McKinnon P, Levine D, Brandel S, Rybak M
Pharmacotherapy
. 2000 Sep;
20(9):1116-9.
PMID: 10999505
Once-daily administration of aminoglycosides (ODA) is effective and safe for many indications. By optimizing pharmacodynamic principles, it enhances bactericidal activity and minimizes toxicity. Its use for the treatment of enterococcal...
7.
Neuhauser M, McKinnon P, Hershberger E, Rybak M
Pharmacotherapy
. 2000 May;
20(5):554-61.
PMID: 10809342
Study Objective: Our institution developed dosing guidelines for patients with renal impairment based on pharmacokinetic data and class-specific pharmacodynamics. Ceftizoxime was chosen as a model agent to evaluate if the...
8.
Murry K, McKinnon P, Mitrzyk B, Rybak M
Pharmacotherapy
. 1999 Nov;
19(11):1252-60.
PMID: 10555931
Study Objective: To characterize nephrotoxicity associated with an individualized serum concentration target-specific, once-daily aminoglycoside (ODA) program. Design: Concurrent and retrospective study. Setting: University-affiliated trauma hospital. Patients: Two hundred patients treated...
9.
McKinnon P, Neuhauser M
Pharmacotherapy
. 1999 Jul;
19(6):724-33.
PMID: 10391418
Study Objective: To evaluate the efficacy and cost of treatment with two beta-lactam/beta-lactamase-inhibitor combinations. Design: Retrospective, open-label multicenter study. Setting: Fifty-four hospitals across the United States. Patients: Eight hundred ninety...
10.
Karam C, McKinnon P, Neuhauser M, Rybak M
Pharmacotherapy
. 1999 Apr;
19(3):257-66.
PMID: 10221365
An approach to minimize monitoring of vancomycin therapy was evaluated in 120 patients, and results were compared with data from 120 patients in whom vancomycin therapy was monitored and adjusted...